Leukemia, Myeloid, Chronic-Phase (CML-CP) Clinical Trial
Official title:
Treatment With Second Generation TYROSINE KINASE INHIBITORS (2G TKI) Post Imatinib Failure: Factors Predicting Response and Predictive Value of Response
The purpose of this study is to determine predictive value of Hammersmith score on Complete Cytogenetic Response (CCyR).
Historic cohort prolonged by a 12-month follow-up period.
Prospective: look forward using periodic observations collected predominantly following
subject enrollment: one year of follow up of patients with CP-CML alive at the time of the
study.
Retrospective: look back using observations collected predominantly prior to subject
selection and enrollment : historical data of patients with CP-CML initiated with a 2G TKIs
post-imatinib failure (resistance or intolerance) between 1-Jan-2005 and 30-June-2009.
The inclusion of a historical cohort will allow a rapid enrollment of a large number of
patients of this rare pathology, while the prospective follow up of this cohort would allow
long term data to be obtained, including the assessment of the impact on survival and
appreciate the patient's quality of life (QoL), compliance and satisfaction.
;
Observational Model: Cohort, Time Perspective: Prospective